ENTERSEKT
2.9.2020 11:02:05 CEST | Business Wire | Press release
Entersekt , a leader in device identity and omnichannel authentication, today announced a partnership with NuData Security , a Mastercard company. This agreement allows the fintech to tightly integrate NuData’s behavioral analytics solution NuDetect with the Entersekt Secure Platform.
NuDetect leverages device and behavioral data to distinguish legitimate users from high-risk ones in real-time. By doing so, it frees genuine account holders to transact unimpeded by security hurdles. In cases where greater certainty is required, a step-up authentication process is triggered. The latter may take the form of an in-app push prompt, a FIDO-certified security key, or any of a number of options available from Entersekt.
Built on multi-patented customer authentication and endpoint security technology, the Entersekt Secure Platform lays a secure foundation for rapid deployment of innovative new digital banking and payments services. Central to the system is digital-certificate-based consumer device ID, seamlessly transforming mobile apps and desktop browsers into regulatory compliant second factors of authentication.
“NuDetect complements Entersekt’s strong device ID with an inherent factor to seamlessly tie the human to the device and brings a new dimension to our regulatory compliant strong authentication suite,” said Dewald Nolte , chief strategy officer at Entersekt. “By combining our leading technologies, we unlock new ways to remove friction for users interacting online, on web or mobile. The combination is like none other on the market, in usability and security, and is another exciting leap forward in our mission to make the digital world safer and more user-friendly.”
“The COVID-19 pandemic led many consumers to shift more of their shopping online during the first half of this year. Our analysts saw a 500% increase in account creation fraud alone during this period, reinforcing the need to leverage state-of-the-art technologies that differentiate between valid users and bad actors,” said Michelle Hafner, senior vice president, NuData Security.1 “By adding behavioral analytics to the Entersekt Secure Platform, we provide an additional layer of protection while simultaneously reducing friction and improving the customer experience.”
NuDetect helps to minimize friction and accurately verify good users across the entire user journey (login, account creation, online checkout, and more). The functionality is available to all institutions using the Entersekt Secure Platform, regardless of their card brand affiliations.
About Entersekt
Entersekt is a leading provider of strong device identity and customer authentication software. Financial institutions and other large enterprises in countries across the globe rely on its multi-patented technology to communicate with their clients securely, protect them from fraud, and serve them convenient new experiences irrespective of the channel or device in use. They have repeatedly credited the Entersekt Secure Platform with helping to drive adoption, deepen engagement, and open opportunities for growth, all while meeting their compliance obligations with confidence.
1 NuData, 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005208/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom